KICVentures leading $25M Raise to Finance AxioMed Multilevel Cervical IDE Study

INVESTing in improving HEALTHCARE

KICVentures is a healthcare growth & buyout private equity investment holding company focused in spine

KICVentures is the healthcare investment holding company for Kingsley Investment Company, founded in 2005 by ex-Arthur Andersen (Accenture) Management Consultant, Doctorpreneur, Dr. Kingsley R. Chin, a Harvard-trained, Orthopedic Spine Surgeon. Our portfolio features revenue generating & profitable companies.



There's a great need for private equity companies with strong healthcare expertise who can find success for their investors by investing in improving healthcare as the primary investment thesis. 


Provide investors with recurring returns possibilities leveraging our decades of expertise to invest in improving healthcare by buying out and growing profitable healthcare companies.


Develop innovative technologies, improve physician-patient services, and provide digital platforms for global access to affordable healthcare.


  1. Medical Devices

  2. Physician Services

  3. Digital Health Platforms

Investment Thesis

  1. Growth & buyout of healthcare companies

  2. Increase value over 5 times within 3-5 years

  3. Major acquisitions every 2 years

  4. Re-invest revenues + capital to execute long-term nimble strategies


Medical Device Focus


Disc Replacement



Dynamic Stabilization



Spine Frontiers #1.jpg


Founder | CEO

  • Born in Jamaica. Titchfield High School.

  • Board Certified Orthopedic Spine Surgeon.

  • Columbia College, Columbia Engineering, Harvard Medical School (honors).

  • Former University of Pennsylvania Chief Orthopedic Spine Surgeon.

  • Business experience at AT&T Bell Labs and Arthur Andersen (Accenture) Management Consulting (Goldman Sachs and Cigna Insurance).

As a doctorpreneur, he brings 30 years of experience at the intersection of healthcare, entrepreneurship and business operations, including 13 years as Founder & CEO of Kingsley Investment Company (KIC) the parent company to KICVentures. Dr. Chin believes good companies become great when they have a winning quarterback, and that’s why he invests in continuous personal leadership development and finds ways to be uniquely competitive. As an example, he is an actively practicing board-certified orthopedic and spine surgeon because of the unique perspective it provides in:

  • Working directly with the medical devices in surgery

  • Working with surgeon colleagues and engineers to improve the devices

  • Working directly with all healthcare stakeholders, especially patients, to understand the market at every level

This 360 degree experience is a unique, game-changing advantage for making investment decisions, measuring the results and having the ability to nimbly make adjustments. Review his CV here

Dr. Chin is the author of the following books:




Co-Founder | CFO

Aditya Humad grew up in India and the Middle East. He graduated from the University of Pennsylvania at the Wharton School of Business and the School of Engineering where he met Dr. Kingsley R. Chin in 2003. His business experience started with J.P.Morgan on Wall Street in New York as a healthcare investment analyst focusing on healthcare M&A, capital raise and restructuring transactions before joining KICVentures in 2009. He has closed multiple M&A deals for KICVentures, most recently AxioMed and NanoFUSE Biologics. He brought focused financial oversight in raising over $30M in equity and debt capital for KICVentures. Review his CV here



Ken Yamada

Chief Business Development Officer

  • 20+ years’ experience covering global medical markets

  • Formerly General Manager and Representative Director of Japan, Senior International Regional Manager of Asia Pacific for Arthrex, global leader in arthroscopy medical devices

  • Graduated from the University of Colorado Denver with an MBA in Finance and Master of Health Service Administration

Ken Yamada is Chief Business Development Officer for KICVentures, serving as a senior executive in a highly-regulated medical device (Orthopedics/Neurosurgery/Spine/Biologics/General Surgery) business covering global markets. He brings solid business practice ranging from strategic planning to tactical and operational execution. He has led the development-end of managing multi-million-dollar global businesses and operations. In addition, he has expertise in identifying markets and developing sales. He has opened new emerging markets, most recently in South East Asia in just 14 months. He has also had success in achieving sales targets by growing Asia over 30% and Latin America by 29%. Ken has developed distribution channels to support sales growth and market expansion and entry. He accomplishes his business objectives by building effective teams and customer advocates. Ken has an MBA and a Master of Science in Health Administration.  He has dual citizenship in the U.S. and Canada and is a permanent resident of Singapore, and speaks both Japanese and English. Review his CV here



Jake Lubinski

Product Acquisition & Commercialization

  • 10+ years’ healthcare experience in operations, orthopedics product management, assembly line manufacturing process efficiency, and disc replacement

  • President of NanoFUSE Biologics

  • Formerly President of AxioMed and Chief Operating Officer of SpineFrontier, directed the acquisition & turnaround of AxioMed

  • M.S. in Mechanical Engineering with concentration in Biomechanics & Spine




Investor Relations Associate

Sheng Ding grew up in China in a family focused on the healthcare industry. He graduated from the University of Miami with a bachelor’s degree in finance and then pursued a master’s degree in Finance from Brandeis University. Before joining KICVentures, he was the co-founder and investment manager of Greatwall Capital Partners, where he raised a fund to focus on healthcare, education and high-tech investments in the US. He joined KICVentures in 2019 and is leading investor relations, outreach and analyzing investment opportunities. He is fluent in English and Mandarin.





The spine industry has gone through a high growth phase and is now consolidating evidenced by multiple acquisitions [1]. We see consolidation and market expansion for the next 5 years as larger players respond to growth pressures and to new innovations in the areas of motion preservation and biologics. For more information on how you can invest in KICVentures provide your information below & we will be in touch.

Name *


 KIC leading $25 M Raise to Finance Axiomed Multilevel Cervical IDE Study

Feb 13, 2019

KICVentures Announces Five New Developments in Spine Surgery

Feb 6, 2019

KICVentures Ramps Up AxioMed Freedom Cervical Disc Manufacturing to Meet OUS Orders and Expand Market Share Rapidly

Dec 27, 2018

Managing Partner of KICVentures and Former J.P. Morgan Analyst Predicts Continued Valuation Growth in the Spine Device Market

Nov 13, 2018

NanoFUSE Biologics LLC Appoints Experienced Orthobiologics Executive Archie Yamada to Accelerate Global Revenue Growth

Jun 27, 2018